Reducing infection rates after prostate biopsy

Nature Reviews Urology

Volumn 11, Issue 2, 2014, Pages 80-86

  Wagenlehner, Florian M E ^a   Pilatz, Adrian ^a   Waliszewski, Przemyslaw ^a   Weidner, Wolfgang ^a   Johansen, Truls E Bjerklund ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; GOLD STANDARD; HUMAN; HUMAN TISSUE; INFECTION RATE; INFECTION RISK; INTESTINE FLORA; INTESTINE PREPARATION; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATITIS; RETROSPECTIVE STUDY; REVIEW; TREATMENT INDICATION; ALGORITHM; BACTERIAL INFECTION; INCIDENCE; MALE; NEEDLE BIOPSY;

ALGORITHMS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; BIOPSY, NEEDLE; HUMANS; INCIDENCE; MALE;

EID: 84891896477     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.322     Document Type: Review

References (63)

1. Zani E. L., Clark O. A., & Rodrigues Netto N. Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD006576. http://dx.doi.org/10.1002/14651858.CD006576.pub2 (2011
2. Carmignani L., et al. Bacterial sepsis following prostatic biopsy. Int. Urol. Nephrol. 44, 1055-1063 (2012
3. Liss M. A., et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J. Urol. 185, 1283-1288 (2011
4. Loeb S., Carter H. B., Berndt S. I., Ricker W., & Schaeffer E. M. Complications after prostate biopsy: data from SEER-Medicare. J. Urol. 186, 1830-1834 (2011
5. Loeb S., et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur. Urol. 61, 1110-1114 (2012
6. Nam R. K., et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J. Urol. 183, 963-968 (2010
7. Grabe M., et al. Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures. World J. Urol. 30, 39-50 (2012
8. Lindstedt S., Lindstrom U., Ljunggren E., Wullt B., & Grabe M. Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur. Urol. 50, 832-837 (2006
9. Loeb S. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int. 109, 1785-1786 (2012
10. Loeb S., et al. Systematic review of complications of prostate biopsy. Eur. Urol. 64, 876-892 (2013
11. Simsir A., Kismali E., Mammadov R., Gunaydin G., & Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy?. Urol. Int. 84, 395-399 (2010
12. Wagenlehner F. M., et al. Infective complications after prostate biopsy: outcome of the global prevalence study of infections in urology (GPIU) 2010 and 2011; a prospective multinational multicentre prostate biopsy study. Eur. Urol. 63, 521-527 (2013
13. Loeb S., Carter H. B., Berndt S. I., Ricker W., & Schaeffer E. M. Is repeat prostate biopsy associated with a greater risk of hospitalization?. Data from SEER-Medicare. J. Urol. 189, 867-870 (2013
14. Nam R. K., et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J. Urol. 189, S12-S18 (2013
15. Mouraviev V., et al. The feasibility of multiparametric magnetic resonance imaging for targeted biopsy using novel navigation systems to detect early stage prostate cancer: the preliminary experience. J. Endourol. 27, 820-825 (2013
16. Pepe P., & Aragona F. Morbidity after transperineal prostate biopsy in 3,000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology 81, 1142-1146 (2013
17. Batura D., & Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J. Antimicrob. Chemother. 68, 247-249 (2013
18. Heidenreich A., et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.11.002
19. Wirth M. P., et al. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms: AWMF Register Nummer (043-022OL) Version 2.0-1. Aktualisierung 2011 [online], http://www.awmf.org/uploads/tx-szleitlinien/043-022OLl-S3-Prostatakarzinom-2011.pdf (2011
20. Scardino P. T. The responsible use of antibiotics for an elevated PSA level. Nat. Clin. Pract. Urol. 4, 1 (2007
21. Ballentine Carter H., et al. Early detection of prostate cancer: AUA guideline. J. Urol. 190, 419-426 (2013
22. Carignan A., et al. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?. Eur. Urol. 62, 453-459 (2012
23. Williamson D. A., et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin. Infect. Dis. 54, 1406-1412 (2012
24. Steensels D., et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy-should we reassess our practices for antibiotic prophylaxis?. Clin. Microbiol. Infect. 18, 575-581 (2012
25. Patel U., et al. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int. 109, 1781-1785 (2011
26. Williamson D. A., Masters J., Freeman J., & Roberts S. Travel-associated extended-spectrum β-lactamase-producing Escherichia coli bloodstream infection following transrectal ultrasound-guided prostate biopsy. BJU Int. 109, E21-E22 (2012
27. Zaytoun O. M., et al. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 77, 1035-1041 (2011
28. Grabe M., et al. Guidelines on urological infections: European Association of Urology Guidelines 224-241 (European Association of Urology, Arnhem, 2013
29. Gonzalez C. M., et al. AUA/SUNA white paper on the incidence, prevention and treatment of complications related to prostate needle biopsy. AUA [online], http://www.auanet.org/resources/white-paper-on-the-incidence-prevention-and-treatment-of-complications-related-to-prostate-needle-biopsy.cfm (2013
30. Laupland K. B., Gregson D. B., Church D. L., Ross T., & Pitout J. D. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin. Microbiol. Infect. 14, 1041-1047 (2008
31. Puig J., et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?. Eur. Radiol. 16, 939-943 (2006
32. Bootsma A. M., Laguna Pes M. P., Geerlings S. E., & Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur. Urol. 54, 1270-1286 (2008
33. Wagenlehner F. M., et al. [Antibiotic prophylaxis in urology]. Urologe A 50, 1469-1480 (2011
34. European Centre for Disease Prevention and Control (ECDC). Proportion of aminopenicillins resistant (R+I) enterococcus faecalis isolates in participating countries in 2012. ECDC [online], http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/maps-report.aspx (2011
35. Al-Hasan M. N., Lahr B. D., Eckel-Passow J. E., & Baddour L. M. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J. Antimicrob. Chemother. 64, 169-174 (2009
36. Tandogdu Z., et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8 year results of the global prevalence of infections in urology study. World J. Urol. http://dx.doi.org/10.1007/s00345-013-1154-8
37. European Centre for Disease Prevention and Control (ECDC). ECDC Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. ECDC [online], http://ecdc.europa.eu/en/publications/Publications/110913-Risk-assessment-resistant-CPE.pdf (2011
38. Qi C., et al. Characterization of ciprofloxacin-resistant escherichia coli isolates among men undergoing evaluation for transrectal ultrasound-guided prostate biopsy: prevalence, clonality, and mechanisms of antimicrobial resistance. J. Urol. 190, 2026-2032 (2013
39. Roach M. B., Figueroa T. E., McBride D., George W. J., & Neal D. E. Jr. Ciprofloxacin versus gentamicin in prophylaxis against bacteraemia in transrectal prostate needle biopsy. Urology 38, 84-87 (1991
40. Kataoka N. [Concentration of antimicrobial agents in male genital organs]. Hinyokika Kiyo 29, 1219-1230 (1983
41. Wagenlehner F. M., Weidner W., Sorgel F., & Naber K. G. The role of antibiotics in chronic bacterial prostatitis. Int. J. Antimicrob. Agents 26, 1-7 (2005
42. Barza M., & Cuchural G. The penetration of antibiotics into the prostate in chronic bacterial prostatitis. Eur. J. Clin. Microbiol. 3, 503-505 (1984
43. Naber K. G., & Sorgel F. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 35, 331-335 (2003
44. Goto T., et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int. J. Urol. 5, 243-246 (1998
45. Naber K. G., et al. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection 19, 30-35 (1991
46. Nishikawa G., et al. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation. Int. J. Antimicrob. Agents 41, 267-271 (2013
47. Nakamura K., et al. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation. J. Chemother. 24, 32-37 (2012
48. Wright W. L., Larking P., & Lovell-Smith C. J. Concentrations of trimethoprim and sulphamethoxazole in the human prostate gland after intramuscular injection. Br. J. Urol. 54, 550-551 (1982
49. Naber K. G., Roscher K., Botto H., & Schaefer V. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int. J. Antimicrob. Agents 32, 145-153 (2008
50. Ongun S., Aslan G., & Avkan-Oguz V. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol. Int. 89, 439-444 (2012
51. Wagenlehner F., Stower-Hoffmann J., Schneider Brachert W., Naber K. G., & Lehn N. Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology. Int. J. Antimicrob. Agents 15, 207-211 (2000
52. Taylor A. K., et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J. Urol. 187, 1275-1279 (2012
53. Jeon S. S., Woo S. H., Hyun J. H., Choi H. Y., & Chai S. E. Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy. Urology 62, 461-466 (2003
54. Abughosh Z., et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J. Urol. 189, 1326-1331 (2012
55. Issa M. M., et al. Formalin disinfection of biopsy needle minimizes the risk of sepsis following prostate biopsy. J. Urol. 190, 1769-1775 (2013
56. Hara R., et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology 71, 191-195 (2008
57. Miller J., Perumalla C., & Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J. Surg. 75, 48-50 (2005
58. Shen P. F., et al. The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian J. Androl. 14, 310-315 (2012
59. Dellinger R. P., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 41, 580-637 (2013
60. Elhanan G., Sarhat M., & Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J. Infect. 35, 283-288 (1997
61. Dellinger R. P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 39, 165-228 (2013
62. Wagenlehner F. M., et al. Diagnosis and management for urosepsis. Int. J. Urol. 20, 963-970 (2013
63. Perletti G., Marras E., Wagenlehner F. M., & Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD009071. http://dx.doi.org/10.1002/14651858.CD009071.pub2 (2013